This article is more than 5 years old. Information may no longer be current.
VIDEO: Results of LEADER trial provide “robust demonstration” of cardiovascular event reduction in high-risk type 2 diabetes
Click Here to Manage Email Alerts
NEW ORLEANS — In this video, Michael T. McDermott, MD, director of endocrinology and diabetes practice at the University of Colorado Hospital, discusses the results of the LEADER trial, which demonstrated that the use of liraglutide reduced the risk for cardiovascular death, nonfatal myocardial infarction and stroke in patients with type 2 diabetes and a history of cardiovascular disease.
McDermott also mentions that the results — presented at the American Diabetes Association Scientific Sessions — demonstrated that the use of liraglutide (Victoza, Novo Nordisk) in these patients did not increase the number of adverse events, and were in fact less common than the group that received placebo.
“So it was really … a home run in terms of a really robust demonstration of cardiovascular event reduction [and] nephropathy reduction without any significant increase in major adverse events,” he said.